The first treatment for low-grade upper tract urothelial cancer (UTUC) has received FDA approval.
Although US health officials were focused on combating coronavirus disease 2019 when mitomycin gel was approved in mid-April, the director of the FDA’s Oncology Center of Excellence said that “patients with cancer and their unique needs continue to be a top priority” for the agency.
Voelker R. Therapy Approved for Hard-to-Treat Upper Tract Urothelial Cancer. JAMA. 2020;323(19):1887. doi:10.1001/jama.2020.7153
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: